These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 10424733)
21. Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. Smith V; Dai F; Spitz M; Peters GJ; Fiebig HH; Hussain A; Burger AM J Chemother; 2009 Nov; 21(5):542-9. PubMed ID: 19933046 [TBL] [Abstract][Full Text] [Related]
22. Quantification of telomerase activity by direct scintillation counting. Kazmer S; Pan KM; Vassilev L J Biochem Biophys Methods; 1999 Aug; 40(3):113-7. PubMed ID: 10487165 [TBL] [Abstract][Full Text] [Related]
23. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619 [TBL] [Abstract][Full Text] [Related]
24. Anticancer therapy targeting telomeres and telomerase : current status. Parkinson EK; Minty F BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621 [TBL] [Abstract][Full Text] [Related]
25. Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. Park KH; Rha SY; Kim CH; Kim TS; Yoo NC; Kim JH; Roh JK; Noh SH; Min JS; Lee KS; Kim BS; Chung HC Int J Oncol; 1998 Sep; 13(3):489-95. PubMed ID: 9683783 [TBL] [Abstract][Full Text] [Related]
26. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Asai A; Kiyozuka Y; Yoshida R; Fujii T; Hioki K; Tsubura A Anticancer Res; 1998; 18(3A):1465-72. PubMed ID: 9673357 [TBL] [Abstract][Full Text] [Related]
27. Telomerase Inhibitor TMPyP4 Alters Adhesion and Migration of Breast-Cancer Cells MCF7 and MDA-MB-231. Konieczna N; Romaniuk-Drapała A; Lisiak N; Totoń E; Paszel-Jaworska A; Kaczmarek M; Rubiś B Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151281 [TBL] [Abstract][Full Text] [Related]
28. Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: in vitro studies with fresh human tumor samples. Faraoni I; Graziani G; Turriziani M; Masci G; Mezzetti M; Testori A; Veronesi U; Bonmassar E Lab Invest; 1999 Aug; 79(8):993-1005. PubMed ID: 10462037 [TBL] [Abstract][Full Text] [Related]
29. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors. Herbert BS; Pongracz K; Shay JW; Gryaznov SM Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790 [TBL] [Abstract][Full Text] [Related]
30. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Gowan SM; Harrison JR; Patterson L; Valenti M; Read MA; Neidle S; Kelland LR Mol Pharmacol; 2002 May; 61(5):1154-62. PubMed ID: 11961134 [TBL] [Abstract][Full Text] [Related]
31. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Shammas MA; Shmookler Reis RJ; Akiyama M; Koley H; Chauhan D; Hideshima T; Goyal RK; Hurley LH; Anderson KC; Munshi NC Mol Cancer Ther; 2003 Sep; 2(9):825-33. PubMed ID: 14555701 [TBL] [Abstract][Full Text] [Related]
32. Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines. Ceja-Rangel HA; Sánchez-Suárez P; Castellanos-Juárez E; Peñaroja-Flores R; Arenas-Aranda DJ; Gariglio P; Benítez-Bribiesca L Tumour Biol; 2016 Sep; 37(9):11917-11926. PubMed ID: 27072825 [TBL] [Abstract][Full Text] [Related]
33. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Kelland LR Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745 [TBL] [Abstract][Full Text] [Related]
34. Correlation of telomerase activity and telomere length to chemosensitivity. Kiyozuka Y Methods Mol Med; 2005; 111():97-108. PubMed ID: 15911975 [TBL] [Abstract][Full Text] [Related]
35. Control of telomere length by the human telomeric protein TRF1. van Steensel B; de Lange T Nature; 1997 Feb; 385(6618):740-3. PubMed ID: 9034193 [TBL] [Abstract][Full Text] [Related]
36. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Parsch D; Brassat U; Brümmendorf TH; Fellenberg J Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350 [TBL] [Abstract][Full Text] [Related]
37. Long-term in vitro treatment with telomerase inhibitor MST-312 induces resistance by selecting long telomeres cells. Morais KDS; Arcanjo DDS; de Faria Lopes GP; da Silva GG; da Mota THA; Gabriel TR; Rabello Ramos DDA; Silva FP; de Oliveira DM Cell Biochem Funct; 2019 Jun; 37(4):273-280. PubMed ID: 31012504 [TBL] [Abstract][Full Text] [Related]
38. Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors. Saraswati AP; Relitti N; Brindisi M; Gemma S; Zisterer D; Butini S; Campiani G Drug Discov Today; 2019 Jul; 24(7):1370-1388. PubMed ID: 31136800 [TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. Fujimori J; Matsuo T; Shimose S; Kubo T; Ishikawa M; Yasunaga Y; Ochi M J Orthop Res; 2011 Nov; 29(11):1707-11. PubMed ID: 21590716 [TBL] [Abstract][Full Text] [Related]